NEW TRENDS I N THE DETECTION AND TREATMENT OF RETINITIS PIGMENTOSA (REVIEW)

  • A. V. Korzhavina RUDN University
Keywords: ophthalmology, retinitis pigmentosa, retina, rods, cones, pigment epithelium, heredity, rhodopsin, degenerative diseases, genetic engineering

Abstract

The review article discusses new research and trends in the treatment of retinitis pigmentosa. The genetic basis for the development of this group of degenerative conditions can be a number of mutations. The pathogenesis of retinitis pigmentosa is quite complex and requires detailed study taking into account the morphology and functioning of photoreceptor cells. To date, there is no single treatment regimen for this Diseases, therefore, its careful study is an important issue of modern ophthalmology.

Areas covered. This review covers standard and innovative diagnostic techniques and complementary examinations needed for the evaluation and treatment of RP. It includes chapters on the assessment of visual function, retinal morphology, and genotyping.

References

References

Verbakel SK,van Huet RAC,Boon CJF,den Hollander AI,Collin RWJ,Klaver CCW,Hoyng CB,Roepman R,Klevering BJ, Non-syndromic retinitis pigmentosa. Progress in retinal and eye research. 2018 Mar 27

Wolfrum U,Nagel-Wolfrum K, [The Usher Syndrome, a Human Ciliopathy]. Klinische Monatsblatter fur Augenheilkunde. 2018 Mar

Yang YJ,Peng J,Ying D,Peng QH, A Brief Review on the Pathological Role of Decreased Blood Flow Affected in Retinitis Pigmentosa. Journal of ophthalmology. 2018

da Cruz L, Coley BF, Dorn J, Merlini F, Filley E, Christopher P, Chen FK, Wuyyuru V, Sahel J, Stanga P, Humayun M, Greenberg RJ, Dagnelie G; Argus II Study Group. The Argus II epiretinal prosthesis system allows letter and word reading and long-term function in patients with profound vision loss. Br J Ophthalmol 2013 May;97(5):632-6.

Luo YH, Zhong JJ, da Cruz L. The use of Argus® II retinal prosthesis by blind subjects to achieve localisation and prehension of objects in 3-dimensional space. Graefes Arch Clin Exp Ophthalmol. 2014 Dec 31. [Epub ahead of print].

Stronks HC, Dagnelie G. The functional performance of the Argus II retinal prosthesis. Expert Rev Med Devices. 2014 Jan;11(1):23-30.

O’Neal TB, Luther EE. Retinitis Pigmentosa. [Updated 2021 Aug 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan

Zeitz C, Friedburg C, Preising MN, Lorenz B. [Overview of Congenital Stationary Night Blindness with Predominantly Normal Fundus Appearance]. Klin Monbl Augenheilkd. 2018 Mar;235(3):281-289.

Grover S, Apushkin MA, Fishman GA: Topical Dorzolamide for the treatment of cystoid macular edema in patients with retinitis pigmentosa. Am J Ophthalmol. 2006; 141(5):850-858.

Bakthavatchalam M, Lai FHP, Rong SS, Ng DS, Brelen ME. Treatment of cystoid macular edema secondary to retinitis pigmentosa: a systematic review. Surv Ophthalmol. 2018 May-Jun;63(3):329-339. doi: 10.1016/j.survophthal.2017.09.009. Epub 2017 Oct 5. PMID: 28987613.

Ghodasra DH, et al. Worldwide Argus II implantation: recommendations to optimize patient outcomes. BMC Ophthalmol. 2016 May 6;16:52. doi: 10.1186/s12886-016-0225-1.

deCruz et al. Five-Year Safety and Performance Results from the Argus II Retinal Prosthesis. Ophthalmology. 2016 Oct;123(10):2248-54.

Stronks HC, Dagnelie G. The functional performance of the Argus II retinal prosthesis. Expert Rev Med Devices. 2014 Jan;11(1):23-30.

Ghodasra DH, Chen A, Arevalo JF, Birch DG, Branham K, Coley B, Dagnelie G, Juan ED; Devenyi RG, Dorn JD, Fisher A, Geruschat DR, Gregori NZ, Greenberg RJ, Hahn P, Ho AC, Howson A, Huang S, Iezzi R, Khan N, Lam BL, Lim JI, Locke KG, Markowitz M, Ripley AM, Rankin M, Schimitzek H, Tripp F, Weiland JD, Yan J, Zacks DN, Jayasundera KD, Jayasundera KT. Worldwide Argus II Implantation: Recommendations to Optimize Patient Outcomes. BMC Ophthalmology 2016;16(1):52.

Published
2022-04-30
How to Cite
Korzhavina, A. (2022). NEW TRENDS I N THE DETECTION AND TREATMENT OF RETINITIS PIGMENTOSA (REVIEW). International Journal of Advanced Studies in Medicine and Biomedical Sciences, (1), 46-53. Retrieved from http://sic-publ.press/index.php/mbs/article/view/34
Issue
No 1 (2022)
Section
Original Articles

Copyright (c) 2023 A. V. Korzhavina

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).